Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management

作者：Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Krishnavathana Varatharajalu, Anusha Shirwaikar Thomas, Yinghong Wang · 发表于：Immunotherapy · 年份：2025 · DOI：10.1080/1750743x.2025.2473305 · 被引用次数：7 · 研究领域：Cancer Immunotherapy and Biomarkers、Colorectal Cancer Treatments and Studies、Colorectal and Anal Carcinomas

Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment by boosting the immune system's ability to target tumors. However, they can also cause serious side effects, particularly in the digestive system. These include immune-related diarrhea, inflammation of the intestines and, less commonly, inflammation of the stomach or esophagus. This review underscores the importance of early detection, accurate diagnosis, and timely treatment to improve patient outcomes. It also highlights the need for further research to develop strategies to reduce gastrointestinal toxicities and enhance the overall effectiveness of ICIs in cancer therapy.